Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Winter solstice 2025 marks the shortest day of the year in the Northern Hemisphere today - 2the 6 Shrewd Beds for seniors: A Complete Survey
- 3Gulf countries continue to face Iran attacks as criticial energy infrastructure at risk
- 4I watched more than 500 new movies this year. These are the 25 best ones.
- 5The most effective method to Pick the Best Material Organization: Insider Tips
- IDF destroys two-kilometer-long Gaza terror tunnel in Beit Lahiya
- Merz: 80% of Syrians in Germany should return in three years
- Israel and Iran continue tit-for-tat attacks
- Lightning on Jupiter could be up to 1 million times stronger than on Earth
- A quick recap of 'Stranger Things' Seasons 1-4, plus key episodes to rewatch before Volume 1 of the final season drops
- The Best 10 Innovation Developments of the Year
- 7 Popular Vacation destinations In China
- What we know about the Brown University shooting suspect who was found dead, and how police linked him to the MIT killing
- Two reportedly killed as Israel attacks Hezbollah targets in Lebanon
